Showing posts sorted by relevance for query big pharma. Sort by date Show all posts
Showing posts sorted by relevance for query big pharma. Sort by date Show all posts

Sunday, October 24, 2021

Some Americans were primed for vaccine skepticism after decades of mistrust in Big Pharma
insider@insider.com (Allana Akhtar) 

 How distrust in pharmaceutical firms gave rise to the anti-vaxx movement, according to experts in the anti-vaccine movement and the history of Big Pharma. Samantha Lee/Insider

Claims of mismanagement and greed in the pharmaceutical industry may have contributed to vaccine hesitancy.

Of Americans who said they would "definitely not" get a COVID-19 vaccine, 20% say they trust drug companies, according to KFF.

Pharma companies are now lobbying against waiving intellectual property protections for COVID-19 vaccines.


Ten months after the world's first COVID-19 vaccine received an emergency green light for use, the US is still reeling from COVID cases among mostly unvaccinated Americans.

Among Americans who said in a recent survey that they will "definitely not" get a COVID-19 vaccine, only 20% said they trust pharmaceutical companies to provide reliable information, according to Ashley Kirzinger, the associate director of public opinion and survey research at the Kaiser Family Foundation.

Pharmaceutical companies large and small are responsible for advancements in medical treatments that have helped cure diseases, relieve chronic pain, and save lives. Several developed COVID-19 vaccines that are highly effective at preventing severe disease.

But publicized claims of mismanagement and greed among some of the world's largest pharmaceutical companies, collectively known as Big Pharma, have eroded public trust and, in turn, have contributed to vaccine hesitancy among some Americans, experts told Insider.

"In the '50s, after World War II, the drug industry was highly respected; they saved hundreds of thousands of lives," Gerald Posner, investigative journalist and the author of "Pharma: Greed, Lies, and the Poisoning of America," said in an interview. "They lost that over decades of greed and mismanagement."

Now, as some pharmaceutical companies lobby to keep their COVID-19 vaccine formulas out of the hands of manufacturers in low-income countries (thereby maximizing profits from the life-saving shot), some Americans may develop a renewed distrust of Big Pharma, Posner said.

"[Pharmaceutical companies] are behaving as if they have absolutely no responsibility beyond maximizing the return on investment," Tom Frieden, infectious disease expert and a former head of the Centers for Disease Control and Prevention, told The New York Times.

Skepticism of Big Pharma has been decades in the making


American trust in Big Pharma reached a peak in the early-to-mid 20th century, when the pharmaceutical industry ushered in life-saving treatments like penicillin and vaccines, as Patrick Radden Keefe reports in his book "Empire of Pain."

Public trust started to erode, however, with the invention and widespread adoption of addictive drugs, Keefe reported. Gallup, whose polling has placed pharmaceutical companies as America's least liked industry for the past two decades, attributes the public's dislike to the companies' high drug prices, tremendous lobbying budgets, and their roles in the opioid epidemic.

Over the last 50 years, lawsuits began piling up against pharmaceutical companies, including those that developed COVID-19 vaccines.

In 2013, Johnson & Johnson settled a federal investigation involving marketing fraud of several drugs, including one to treat dementia patients. Reuters reported in 2018 that small amounts of asbestos were found in the company's baby powder between the early 1970s and the early 2000s. The report claimed that the company failed to disclose that information, which Johnson & Johnson has repeatedly denied. The company is facing thousands of lawsuits alleging that the talc-based products caused cancer and mesothelioma.

Last year, 46 US states sued 26 drug makers, including Pfizer, over allegations of conspiring to drive up drug prices. (Pfizer told Reuters the company did not behave in unlawful conduct.)

In 2009, Pfizer, which produced the first FDA-approved COVID-19 vaccine, paid the second-largest healthcare fraud settlement in US history to settle accusations of misleading advertising of an anti-inflammatory drug. When asked to comment on this article, a Pfizer spokesperson told Insider the company "cannot speculate why some remain vaccine hesitant, but vaccination remains one of the best tools we have to help protect lives and work to achieve herd immunity."

The anti-vaccine movement in the US, which gained momentum in the early 2000s, has tried to use drug industry scandals to discourage parents from inoculating their children, according to Dr. Stewart Lyman, the owner of Lyman Biopharma Consulting LLC and a vaccine advocate.

In the mid-2010s, measles in children began resurfacing despite the CDC having declared measles as eliminated from the US in 2000. Some anti-vaccine believers fought for personal exemptions for vaccine mandates during local measles outbreaks.

Others within the movement said not to trust the pharmaceutical company Merck with vaccines because of a whistleblower complaint claiming that the company overstated the effectiveness of the shot. (Merck did not respond to Insider's request for comment.)
© Provided by Business Insider "In the fifties, after World War II, the drug industry was highly respected; they saved hundreds of thousands of lives," Gerald Posner, and investigative journalist and the author of "Pharma: Greed, Lies, and the Poisoning of America, said in an interview. "They lost that over decades of greed and mismanagement." 
Erik McGregor/LightRocket via Getty Images


Big Pharma's business model drives mistrust among vaccine skeptics

Kirzinger told Insider anecdotal data from Kaiser suggests some Americans are hesitant about the COVID-19 vaccine due to how pharmaceutical industries profit from shots, despite the shots being rigorously tested by scientists before given to the public and built on decades of research.

Vaccine makers have made billions in revenue by selling the shots to countries, and soaring pharmaceutical stocks have minted a class of "vaccine billionaires."

"[Some vaccine hesitant Americans] are talking about distrust of Pharma because they think that they're mostly concerned about profits rather than safety," Kirzinger said.

The price of the life-saving hormone insulin, for example, has skyrocketed in the last decade, costing diabetes patients around $300 for a 10-millimeter vial, up from about $93 in 2009. Many low-income Americans have resorted to rationing insulin to make it last longer, and lawmakers are pressuring drug companies to reduce costs.

Still, pharma companies are currently lobbying President Joe Biden to prevent him from waiving intellectual property protections for COVID-19 vaccines - thereby keeping manufacturers in poor countries from making life-saving shots for vulnerable populations.

And while some vaccine makers like Johnson & Johnson have sold COVID-19 vaccines at cost, others, including Pfizer and Moderna, have sold them for a profit.

Wednesday, January 29, 2020

A secret reason Rx drugs cost so much: 
A global web of patent laws protects Big Pharma

January 28, 2020 Faisal Chaudhry


Advocates for lower drug prices held a vigil on Sept. 5, 2019 outside of Eli Lilly in New York City, honoring those who have lost their lives due to the high cost of insulin. Eric McGregor/LightRocket via Getty Images

The high price of insulin, which has reached as much as US$450 per month, has raised outrage across the country. Sen. Bernie Sanders (I-Vt.) has called it a national embarrassment, wondering why U.S. residents should have to drive to Canada to buy cheaper insulin.


As a legal scholar who focuses on the contradictory role of property rights on economic well-being, including through the role of intellectual property rights, my research makes it clear that drug pricing is far more complicated than any candidate on the debate stage has time to explain.

To fully understand these complexities requires looking at a web of international patent law and trade agreements.    

 
Insulin was discovered almost 100 years ago, saving the lives of many people with diabetes. Its soaring costs in recent years has brought outcries from patients and politicians. John Fredricks/NurPhoto via Getty Images

Why no generic insulin?

Scientists working in Canada’s public sector discovered insulin nearly a century ago. The first techniques for synthesizing the compound, which should have more readily allowed for the production of generic versions, emerged some four decades ago. Yet today insulin remains unavailable in any significant generic version.

One of the three companies that control 90% of the world insulin market, Eli Lilly, recently did bow to public pressure by announcing a forthcoming “authorized generic” version called Lispro. But that could still run some people $140 per prescription.

U.S. consumers are not alone in facing high prices of insulin and other life-saving drugs. For the last two decades, intense controversy has raged around multinational pharmaceutical giants being able to monopolize access to vital medicines the world over. A key means of doing so is through the legal power of patents, and the monopoly-like profits – or what some experts call unearned economic rents – they guarantee.


Think of rent as a windfall gained for making little effort of one’s own. Being “unearned,” rents are thus usually distinguished from ordinary business profits. In this way, they are comparable to the fees a medieval lord would charge for access to cropland on a vast estate.

To fully explain the problem of economic rents and access to medicines, however, we need to look still further: to the controversies that have swirled around pharmaceutical patents in countries far less wealthy than the U.S.

A worldwide problem, but hidden from sight

For more than 20 years, in various parts of Africa, Asia and Latin America, countries have been battling a global system of rent-taking, or “rentierism” for short, that disproportionately benefits Big Pharma.

This state of affairs could not exist without the government officials whom Big Pharma has lobbied successfully in wealthy countries. Patents and other intellectual property rights allow the multinationals to capture rent by evading competition for years on end.

This global battle around pharmaceutical patents began in earnest with the founding of the World Trade Organization(WTO) in 1994. This included an annex agreement on intellectual property rights known as the Trade-Related Aspects of Intellectual Property Rights.

Many countries already allowed for patents before 1994, but only on “processes” of manufacture or synthesis. After 1994, WTO member countries were required to extend patents to the vital end products of such processes as well.

For inhabitants of developing countries, whose greatest public health problems at the time derived from diseases like malaria, tuberculosis and HIV-AIDS, this crystallized various questions of great import. Should the agreements enable Big Pharma’s monopoly-like patent rights to trump the ability of the sick and dying to obtain generic versions of life savings medicines? And if so, to what extent?

By 2001, all WTO member states officially had conceded the rights of developing countries to take measures to increase access to lifesaving medicines. But Big Pharma and its allies have never relented in pressing for more, not less, stringent intellectual property protections around the world.

Shaky justifications

Since 1994, Big Pharma has imposed ever more severe requirements around patent rights. They have insisted that patent rights are necessary to “incentivize” the availability of drugs for conditions like tuberculosis and malaria that, having no markets in the developed world, require guaranteed premiums from whatever countries they are sold in.

Yet for just as long, critics have alleged that Big Pharma typically uses inflated, misleading or otherwise opaque cost data to tout the billions of dollars it claims to spend on drug development. Likewise, critics have continuously called attention to the way that most drug development is built on publicly funded research.

And, finally, critics have never stopped highlighting the fact that Big Pharma long ago largely abandoned research and development for drugs for infectious ailments in developing nations, and increasingly switched to spending on blockbuster noninfectious disease drugs.

Yet as diseases such as cancer and heart disease begin to take an even greater toll in the developing world, patents will extract an ever greater toll on patient populations across the world.

In a developing world where public health problems increasingly look similar to the developed world’s, in fact, multinational pharmaceutical corporations could become better – not worse – placed to expand their profits by tapping new markets for drugs like insulin and beta blockers.

A convergence between the sick across the globe

One unexpected lesson from this is that ordinary people around the world will increasingly find themselves in the same boat when it comes to accessing the medicines they need.

Therefore, if countries in the developing world are forced to give up the fight against patent rentierism, it should be a concern both to their own residents and to residents of wealthy countries too.

Just this past September, for example, Indian Prime Minister Narendra Modi signaled that his country – which has a robust generic drugs industry that supplies low-cost medicines to people around the world – was ready to concede to the demands of Big Pharma by moving toward abdicating his country’s vital role as “the pharmacy of the world.” India has now signed an interim trade agreement with the Trump administration that will require it to more strictly enforce the patent rights of pharmaceutical multinationals, with the latest news reports indicating it may even now be finalized.

Over the course of the current battle for the Democratic nomination, many will have heard about the plight of residents of Michigan who are left asking how insulin costs 10 times in the U.S. what it costs 10 minutes away across our northern border.

Given the larger conversation about patent rents and access to medicines that we should be having, however, it behooves those of us who live in places like the U.S. to look not only to Canada but to what is happening around the world, where the sick and dying face increasingly similar ailments – and fights – as our own.

Author
Faisal Chaudhry
Professor of Law, University of Dayton
Disclosure statement
Faisal Chaudhry has received funding from the Mellon Foundation, the American Council of Learned Societies, the Fulbright Program of the Bureau of Educational and Cultural Affairs of the United States Department of State and Harvard University.
Partners

Saturday, January 30, 2021

 PUBLIC OWNERSHIP OF BIG PHARMA NOW!

New Report From Rep. Katie Porter Reveals How Big Pharma Pursues 'Killer Profits' at the Expense of Americans' Health

"It's time we reevaluate the standards for approving these mergers. It's time we pass legislation to lower drug prices. And it's time we rethink the structure of leadership at big pharmaceutical companies."



A new report from Rep. Katie Porter (D-Calif.) takes pharmaceutical companies to task for their merger and acquisition activities. (Photo: Tom Williams/CQ-Roll Call, Inc.)

A new report from Rep. Katie Porter (D-Calif.) reveals how Big Pharma uses mergers and acquisitions to increase profits at the expense of Americans' healthcare. (Photo: Tom Williams/CQ-Roll Call, Inc.) 

Rep. Katie Porter on Friday published a damning report revealing the devastating effects of Big Pharma mergers and acquisitions on U.S. healthcare, and recommending steps Congress should take to enact "comprehensive, urgent reform" of an integral part of a broken healthcare system. 

"In 2018, the year that Donald Trump's tax giveaway to the wealthy went into effect, 12 of the biggest pharmaceutical companies spent more money on stock buybacks than on research and development."
—Report

The report, entitled Killer Profits: How Big Pharma Takeovers Destroy Innovation and Harm Patients, begins by noting that "in just 10 years, the number of large, international pharmaceutical companies decreased six-fold, from 60 to only 10."

While pharmaceutical executives often attempt to portray such consolidation as a means to increase operational efficiency, the report states that "digging a level deeper 'exposes a troubling industry-wide trend of billions of dollars of corporate resources going toward acquiring other pharmaceutical corporations with patent-protected blockbuster drugs instead of putting those resources toward' discovery of new drugs."

Merger and acquisition (M&A) deals are often executed to "boost stock prices," to "stop competitors," and to "acquire an innovative blockbuster drug with an enormous prospective revenue stream." 

"Instead of spending on innovation, Big Pharma is hoarding its money for salaries and dividends," the report says, "all while swallowing smaller companies, thus making the marketplace far less competitive." 

The report calls M&As "just the tip of the iceberg of pharmaceutical companies' anti-competitive, profit-driven behaviors":

Pharmaceutical companies often claim that lowering the prices of prescription drugs in the United States would devastate innovation. Yet, as prices have skyrocketed over the last few decades, these same companies' investment in research and development have failed to match this same pace. Instead, they've dedicated more and more of their funds to enrich shareholders or to purchase other companies to eliminate competition.

"In 2018, the year that [former President] Donald Trump's tax giveaway to the wealthy went into effect, 12 of the biggest pharmaceutical companies spent more money on stock buybacks than on research and development," the report notes.

Some key findings from the report:

  • Big pharmaceutical companies are not responsible for most major breakthroughs in new drugs. Rather, innovation is driven in small firms, which are often spun off of taxpayer-funded academic research. These small labs are then purchased by giant firms after they've assumed the risk needed to develop a blockbuster drug;
  • Instead of producing lifesaving drugs for diseases with few or no cures, large pharmaceutical companies often focus on small, incremental changes to existing drugs in order to kill off generic threats to their government-granted monopoly patents; and
  • Mergers in the pharmaceutical industry have had an overall negative effect on innovation, taking what little competition existed in the industry and completely destroying it.

"Competition is central to capitalism," Porter said in a press release introducing the report. "As our report shows, Big Pharma has little incentive to invest in new, critically needed drugs. Instead, pharmaceutical giants are free to devote their resources to acquiring smaller companies that might otherwise force them to compete."

"Lives are on the line; it's clear the federal government needs to reform how it evaluates healthcare mergers and patent abuses," Porter added. 

To that end, Porter's report recommends the following actions:

"It's time we reevaluate the standards for approving these mergers," the report concludes. "It's time we pass legislation to lower drug prices. And it's time we rethink the structure of leadership at big pharmaceutical companies. Together, these strategies can help us bring more innovative, and critically needed, cures and treatments to market."

Sunday, July 14, 2024

Big Food, Big Pharma, Big Nightmare: An Interview with Martha Rosenberg



 
 JULY 12, 2024
FacebookTwitter

Eli Lilly HQ, Indianapolis. Photo: Jeffrey St. Clair.

The title of Martha Rosenberg’s book – Big Food, Big Pharma, Big Lies – goes right to the heart of her project. The Evanston, Illinois-based Rosenberg – a researcher, journalist, cartoonist and longtime CounterPunch contributor – is taking on more than just the (considerable) damage the drug and agribusiness and food processing companies have wreaked on human and non-human organisms over the last couple of generations. She also delves deeply into the question of how these global corporate leviathans have tried to shape the world to their benefit, doing their utmost to create a culture of complicit doctors, lax regulators and propagandized consumers. All of these actors play a part in sustaining the illusions that keep the big hustle going: e.g., that drug companies and food producers are on our side, that technology is synonymous with progress, that more and newer pills necessarily translates into better health, that what we don’t know about the food we eat and the medications we take won’t hurt us, and that mass advertising of brand-name drugs means a better-informed public.

Big Food is an augmented second edition of Rosenberg’s Born with a Junk Food Deficiency, which came out in 2012. That eye-opening exposé was widely (and mostly favorably) reviewed at the time, including by this writer, who described it in NewCity as “an essential reminder that unless the humane and life-affirming ‘genes’ of accountability, integrity, solidarity, humility and compassion are re-inserted into our society and institutions, the prognosis for our collective well-being is grim.”

Things have only gotten worse in the 12 years since the original edition came out – yet one hears less criticism than in the past, perhaps because, in the post-pandemic era, criticism of the ways of Big Pharma could be misinterpreted as an attack on science. In any event, the flow of new, heavily publicized “diseases” – many of which in the past would have been thought of as minor nuisances – continues unabated, as drug company returns grow while American life expectancy and quality of life decline. Healthcare remains a system in which risks are systematically minimized, non-generic drug prices are grotesquely inflated, and patients are reduced to guinea pigs in the product development and marketing process. From a sociological perspective, Rosenberg’s book is a depiction of the inevitable consequences of a profit-driven medical complex, notably the manufacture of factitious ailments and the over-prescribing of under-tested and potentially dangerous drugs. And on the food side of the equation, we get what Rosenberg aptly terms “the drugstore in your meat” – meat that, at this point, many other countries will not touch.

Well-researched and cogently argued, Big Food, Big Pharma, Big Lies should be on the reading list of every health-conscious person. Penned by an independent reporter with no ties to industry, the book details how corporate wealth – in the form of saturation advertising, MD junkets and honoraria, squadrons of lobbyists and the legalized bribery known as campaign contributions – has corrupted the institutions ostensibly intended to inform and protect us, from the federal regulatory agencies to the universities to the media to the medical profession itself. In the grand old muckraking tradition, Rosenberg reveals to us the underhanded tactics and revolving-door arrangements behind the facade of the so-called “ethical” [i.e., prescription] drug makers, as well as agribusiness. The point is to wake readers from their media-induced trance regarding the vast power and abusive behavior of the industries associated with our two most fundamental needs: health and nourishment.

I communicated with Rosenberg by e-mail about her reissued book and the changes she has witnessed over the dozen years since the first edition came out. What follows is a lightly edited transcript of our Q&A.

What got you interested in this field – i.e., Big Pharma and Big Food – in the first place? Your own encounters with the healthcare system, perhaps?

I probably trace my antipathy toward drug makers to the Pill, which came out in the early 1960s. Some feminists noted that the Pill caused 51 biochemical changes in women–including increased risk of stroke–all because men wouldn’t put on a rubber. Later I worked at Louisiana State University medical school, and I noted more duplicity – including a refusal to call out the carcinogenic nitrites and nitrates in processed meat and water – likely for political and financial reasons.

Your book is about how Big Food and Big Pharma collude with each other to produce a nation of highly medicated but less than thriving people. How does this process work?

As I write in the book, bad food leads people to seek prescriptions for conditions ranging from acid reflux, obesity and diabetes to cardiovascular problems and cancer. Drug makers clean up when people are obese.

However, we may be witnessing a change in the interplay between Big Food and Big Pharma. The advent of GLP agonists like Ozempic and Wegovy has changed the way many people eat. So many people (I should say “rich people,” since the drugs are so expensive) have lost their appetite for fattening junk food that American grocery-buying habits have changed, according to published news reports. Restaurants too have reported a change in patrons’ appetites and preferences.

The GLP agonists have benefited from reports that they reduce addictions and even stroke risks. The cynic in me says they are the new statins. You’ll remember when the statin Lipitor was the bestselling drug in the world and statins were such a medical and Wall Street home run that some people said that the drugs should be added to drinking water. After the statin “gold rush,” when the drugs went off-patent, dangerous side effects were revealed, and medical reports began linking GLP agonists to dangerous gastroenterological effects, which should serve as red flags to anyone paying attention. Surgeons I’ve interviewed, for example, have shared grave concerns about the drugs’ ability to cause delayed gastric emptying.

As you note, disease is now frequently treated as a symptom of drug deficiency, and many doctors are no longer health and lifestyle consultants, but rather harried, over-scheduled drug peddlers. Unless I’m mistaken, it hasn’t always been thus. When and why did things change?

Once upon a time, we had a “concierge” medical business model in which patients paid their doctors directly, and neither insurance companies nor drug makers shaped the economic landscape. Back then, doctors also made house calls.

The economic middlemen have warped the entire purpose of medical care, changing it into a money-making proposition, rather than a way to alleviate disease and pain. As I point out in Big Food, Big Pharma, Big Lies, one of the most dramatic results of this economic takeover is the overriding message that you probably are sick or could be sick and therefore need to “ask your doctor.” Few remember the comforting message that doctors used to intone to nervous patients: “Take two aspirins and call me in the morning” … the point being that you were probably not seriously ill and whatever symptom you had was fairly likely to go away by itself. Now there is money to be made in convincing everybody that they’re ill.

There’s a chapter in the book about the history of hormone replacement therapy (HRT), whose potential side effects – including significantly higher risk of breast cancer, stroke, blood clots, dementia, etc. – have been shown to be much more serious than the menopausal symptoms it treats. Yet on a regular basis, the mainstream media publishes articles extolling the virtues of HRT, as though these large-scale studies about its hazards had never happened. Why does this risky treatment for a non-disease keep rising from the grave, so to speak?

Drug makers seek medications that millions will take most of their lives. They do not make money on short-term prescription like antibiotics (unless they’re used in livestock, which the book addresses). Almost no woman was immune to the drug maker message that aging and menopause were diseases, a message that also played into the sexist premise that an older or less physically attractive woman is worthless. HRT was a cash cow for drug makers who invented the term “perimenopause” so they could start women on the drugs sooner.

When the wheels fell off HRT, drug makers marketed bone drugs to zero in on the one real benefit that HRT could deliver – it strengthened women’s bones. But the bone drugs, called bisphosphonates, were even more pernicious than HRT: by stopping bone turnover, they caused fractures and some women even lost their jaw bones. There are natural and safe treatment for sleep problems, hot flashes and other symptoms of the menopause transition, but drug makers make no money off them.

The book talks about how potent psychoactive drugs are prescribed more and more to the very young, the very old, traumatized returning vets and other captive consumers. What harm does this produce? And is there any trend in the other direction, away from seeing every deviation from a narrowly defined norm as a medicable ailment?

It is estimated that as a much as a quarter of the US population is on antidepressants, which are often prescribed along with other psychoactive drugs. The aggressive marketing of antidepressants has succeeded in redefining what “depression” is and just how “happy” people are supposed to be. If a person isn’t exuberant all the time, there are many possible reasons other than clinical depression, such as a bad job, precarious financial condition, family problems, health status, and certainly social and political issues. The marketing of add-on drugs for “treatment-resistant depression,” which doubles and quadruples profits, can be seen as an admission that the condition was likely not clinical depression to begin with. In fact, about two years ago, definitive research came out of the UK debunking the entire “chemical imbalance” theory on which most psych drugs are marketed.

There’s another downside to the promiscuous marketing of antidepressants, the taking of which now seems almost a rite of passage for young people. Reports now correlate use of SSRI [i.e., selective serotonin reuptake inhibitors] antidepressants with bipolar disorder. It’s only recently that bipolar disorder has become epidemic, a phenomenon that opens up other lucrative prescription avenues. Drug makers prowl social media to make mental illness not just common and acceptable but also cool, and I have personally interviewed young people who are perversely proud of a bipolar diagnosis.

In my opinion, many of the emotional and suicidal problems we now see in young people emanate from the psych drug cocktails they are so routinely given. Young people used to be able to work out their identity questions by themselves. But the process of growing up and finding a solid adult identity is now delayed and sometimes made a permanent challenge by the plethora of psych drugs now being prescribed.

With regard to veterans and active duty service people, I was astounded when I wrote the book to discover how many DOD and VA administrators also served as Pharma consultants, with no firewall at all. Drug makers gravitate toward government entitlement programs such as Medicare, Medicaid and the military because they are an easier sell than to private interests. Taxpayers should be furious.

A major part of your book is about agribusiness, with one chapter titled “The Drugstore in Your Meat.” What are some of those drugs, and what do they do to us?

Few Americans realize that the food sold to us – especially meat – is often banned in other countries. For example, the European Union will not import our hormone-saturated meat, which EU medical officials link to breast and prostate cancer. Asian countries reject the growth drug ractopamine, which is endemic in US agriculture because it produces more weight on animals and thus more profit for meat raisers. To retard bacterial growth, chickens here are dipped in chlorine, which has caused other countries to reject our poultry exports. The notorious “pink slime” – which caused an uproar in US ag markets but is still legal – is made by treating ground beef with ammonia puffs to retard the growth of E. Coli. But ammonia is not allowed in many other countries’ food chains. And vaccines – used to prevent a host of diseases that livestock are susceptible to – are a huge, under-reported part of American meat production. Food animals get dozens of inoculations, and they also ingest heavy metals from other farm medications.

From bird flu to mad cow disease to porcine diarrhea virus to herpes, the diseases that haunt US farms and their treatments would turn any stomach. But news outlets – whose main advertisers are, after all, food companies – seldom report them. Meat producers –especially those who sell “bob” veal [i.e., from newborn calves] – often violate regulations on antibiotics residues. But again, news reports rarely expose these health hazards to consumers, and the information is often available only on little-read government sites.

Why do the regulatory agencies – such as the Food and Drug Administration (FDA) and United States Department of Agriculture (USDA) – do so little regulating and so much kowtowing to corporate power? Would you describe the FDA as a captive agency? Has the drug-testing process been corrupted?

While the FDA has definitely been captured – the Commissioner admitted to 51 financial links to drug makers a few years ago and has gone on record lauding the symbiosis between FDA and Pharma – the USDA was intended to be captured. It was designed to help the agricultural sector and does not presume to serve the public as the FDA is supposed to. Both agencies serve industry over consumers and Congress will do little to help. Why? Because drug makers are among lawmakers’ biggest funders, and lawmakers from ag states are loath to attack the food processors dear to their constituents. There are pure food and drug movements out there, but they are up against tremendous financial forces and need to convince people to vote with their pocketbooks.

Drug testing has become a farce thanks to drug maker machinations. Clinical trials to test if a drug is safe and effective are now run by corporations called contract research organizations (CROs), which are hired by drug companies. CROs design the drug trials, recruit the subjects and help prepare final “submission-for-approval” packages to the FDA. CROs even market new drugs. A few years ago, the largest US-based CRO – Quintiles Transnational – boasted 23,000 employees in 60 countries!

Drug makers often test new products in poor countries, where participants often think they are receiving real medical care and do not realize they are taking a risk. It should also be noted that much, maybe most, drug manufacturing these days is done overseas, where quality issues can and do surface, but production costs are lower.

Your book is about not just bad drugs and bad foods, but also direct-to-consumer (DTC) advertising. This form of attitude-shaping pharmaceutical propaganda, allowed almost nowhere else, permeates TV here. Why is DTC advertising so popular? How does it affect our notions of sickness and health, and the relationship between doctor and patient?

While some medical voices have called for DTC advertising to be made illegal, it’s unlikely to happen, because DTC is probably the most successful marketing vehicle the drug makers have. First of all, advertising works. Second, news outlets and shows are captured by the outrageous revenue these seemingly wall-to-wall DTC ads represent. Third, drug makers no longer have to hire sales reps – who are not always welcomed by doctors – because DTC ads turn viewers into de facto reps, who corner their doctor with the disease they know they have and the drug they know they need thanks to DTC advertising. Ad viewers can be so insistent and adamant in requesting advertised drugs that some medical schools have had to teach doctors what they call “refusal skills.”

Many have pointed out the discrepancy between the laughing, happy models in these ads and the litany of horrific potential side effects – coma, paralysis, brain bleeds, stroke – intoned in the background. It’s been suggested that the “scare track” could somehow perversely sell the drug, in the same way that people are drawn to grisly news stories or murder mysteries.

The original edition of this book came out in 2012. What prompted the update? Have things gotten worse in the last dozen years or so?

Since the first edition of this book, the opioid scandal has erupted, underscoring the corruption and conflicts of interest that characterize the pharmaceutical industry. “Forever chemicals” have become more prominent in food and the environment, with little apparent appetite on the part of regulators to do anything about it. DTC advertising has become so ubiquitous, it sometimes feels like the TV set has turned into one big Pharma Channel. All these trends have gotten worse in the last decade, necessitating a new edition of the book, which I now call Big Food, Big Pharma, Big Lies.

In light of the vast power of the corporate drug and agribusiness industries within a pay-to-play “democracy,” what advice would you give people about protecting their own health?

I recommend that before taking a new drug, do some research on sites such as Public Citizen, the People’s Pharmacy, PharmedOut and AskaPatient. Some well-researched information is available, but you have to dig for it.

Hugh Iglarsh is a Chicago-based writer, editor, critic and satirist. He can be reached at hiiglarsh@hotmail.com.